{"id":"NCT02014467","sponsor":"GlaxoSmithKline","briefTitle":"Denosumab China Phase III Study","officialTitle":"A Twelve-Month Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Chinese Postmenopausal Women With Osteoporosis at Increased Risk of Fracture","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2013-12-18","resultsPosted":"2016-10-31","lastUpdate":"2016-10-31"},"enrollment":486,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis, Postmenopausal"],"interventions":[{"type":"DRUG","name":"Denosumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Elemental Calcium","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin D","otherNames":[]}],"arms":[{"label":"Denosumab 60mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.","primaryOutcome":{"measure":"Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12","timeFrame":"Baseline and Month 12","effectByArm":[{"arm":"Denosumab 60 mg","deltaMin":5.22,"sd":0.274},{"arm":"Placebo","deltaMin":0.79,"sd":0.391}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.7495"}]},"eligibility":{"minAge":"60 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":24},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":367},"commonTop":["Arthralgia","Blood cholesterol increased","Bone density decreased"]}}